Decreased phosphatidylcholine plasmalogens - A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction

Atherosclerosis

Volumn 246, Issue , 2016, Pages 130-140

  Sutter, Iryna ^a,b   Klingenberg, Roland ^c   Othman, Alaa ^a,e   Rohrer, Lucia ^a   Landmesser, Ulf ^b,c,d   Heg, Dierik ^e   Rodondi, Nicolas ^f   Mach, Francois ^g   Windecker, Stephan ^f   Matter, Christian M ^b,c   Lüscher, Thomas F ^b,c   von Eckardstein, Arnold ^a,b   Hornemann, Thorsten ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Acute myocardial infarction; Coronary artery disease; Glycerophospholipids; Sphingolipids

Indexed keywords

CERAMIDE; GLYCEROPHOSPHOLIPID; HEXOSYLCERAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PLASMALOGEN; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; HUMAN; INVESTIGATIVE PROCEDURES; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHATIDYLCHOLINES; PLASMALOGENS; PREDICTIVE VALUE OF TESTS;

EID: 84954168089     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.003     Document Type: Article

References (37)

1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J. Nov 7 2014, 35(42):2929.
2. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature May 19 2011, 473(7347):317-325.
3. Crea F., Liuzzo G. Pathogenesis of acute coronary syndromes. J. Am. Coll. Cardiol. Jan 8 2013, 61(1):1-11.
4. Ekroos K., Janis M., Tarasov K., Hurme R., Laaksonen R. Lipidomics: a tool for studies of atherosclerosis. Curr. Atheroscler. Rep. Jul 2010, 12(4):273-281.
5. Hornemann T., Worgall T.S. Sphingolipids and atherosclerosis. Atherosclerosis Jan 2013, 226(1):16-28.
6. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. Mar 2009, 50(3):574-585.
7. Dashti M., Kulik W., Hoek F., Veerman E.C., Peppelenbosch M.P., Rezaee F. A phospholipidomic analysis of all defined human plasma lipoproteins. Sci. Rep. 2011, 1:139.
8. Hammad S.M., Pierce J.S., Soodavar F., et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. Oct 2010, 51(10):3074-3087.
9. Meikle P.J., Wong G., Tsorotes D., et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. Nov 2011, 31(11):2723-2732.
10. Nishimukai M., Maeba R., Ikuta A., et al. Serum choline plasmalogens-those with oleic acid in sn-2-are biomarkers for coronary artery disease. Clin. Chim. Acta Nov 1 2014, 437:147-154.
11. Pruzanski W., Stefanski E., de Beer F.C., de Beer M.C., Ravandi A., Kuksis A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. Jul 2000, 41(7):1035-1047.
12. Kostara C.E., Papathanasiou A., Psychogios N., et al. NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease. J. Proteome Res. May 2 2014, 13(5):2585-2598.
13. Sutter I., Velagapudi S., Othman A., et al. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis Aug 2015, 241(2):539-546.
14. Kontush A., Chapman M.J. Lipidomics as a tool for the study of lipoprotein metabolism. Curr. Atheroscler. Rep. May 2010, 12(3):194-201.
15. Stegemann C., Drozdov I., Shalhoub J., et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ. Cardiovasc Genet. Jun 2011, 4(3):232-242.
16. Hannun Y.A., Obeid L.M. Many ceramides. J. Biol. Chem. Aug 12 2011, 286(32):27855-27862.
17. Penno A., Reilly M.M., Houlden H., et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J. Biol. Chem. Apr 9 2010, 285(15):11178-11187.
18. Zitomer N.C., Mitchell T., Voss K.A., et al. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J. Biol. Chem. Feb 20 2009, 284(8):4786-4795.
19. Reiser H., Klingenberg R., Hof D., et al. Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arterioscler. Thromb. Vasc. Biol. Aug 2015, 35(8):1872-1879.
20. Cavelier C., Rohrer L., von Eckardstein A. ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ. Res. Nov 10 2006, 99(10):1060-1066.
21. Haimi P., Uphoff A., Hermansson M., Somerharju P. Software tools for analysis of mass spectrometric lipidome data. Anal. Chem. Dec 15 2006, 78(24):8324-8331.
22. Sutter I., Park R., Othman A., et al. Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate. J. Lipid Res. Jun 20 2014, 55(8):1730-1737.
23. Othman A., Rutti M.F., Ernst D., et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?. Diabetologia Feb 2012, 55(2):421-431.
24. Yekutieli D., Benjamini Y. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics. J. Stat. Plan. Inference Dec 1 1999, 82(1-2):171-196.
25. Graessler J., Schwudke D., Schwarz P.E., Herzog R., Shevchenko A., Bornstein S.R. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One. 2009, 4(7):e6261.
26. Pietilainen K.H., Sysi-Aho M., Rissanen A., et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS One. 2007, 2(2):e218.
27. Laurila P.P., Surakka I., Sarin A.P., et al. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler. Thromb. Vasc. Biol. Apr 2013, 33(4):847-857.
28. Maeba R., Maeda T., Kinoshita M., et al. Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with aging. J. Atheroscler. Thromb. Feb 2007, 14(1):12-18.
29. Wallner S., Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids. Sep 2011, 164(6):573-589.
30. Reiss D., Beyer K., Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem. J. May 1 1997, 323(Pt 3):807-814.
31. Jurgens G., Fell A., Ledinski G., Chen Q., Paltauf F. Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens. Chem. Phys. Lipids Aug 1 1995, 77(1):25-31.
32. Maeba R., Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. Jan 2003, 44(1):164-171.
33. Bertea M., Rutti M.F., Othman A., et al. Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis. 2010, 9:84.
34. Quehenberger O., Armando A.M., Brown A.H., et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. Nov 2010, 51(11):3299-3305.
35. Sattler K.J., Elbasan S., Keul P., et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res. Cardiol. Nov 2010, 105(6):821-832.
36. Argraves K.M., Sethi A.A., Gazzolo P.J., et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011, 10:70.
37. Luscher T.F., Landmesser U., von Eckardstein A., Fogelman A.M. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. Jan 3 2014, 114(1):171-182.